Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blue light therapy could speed healing of breast abscesses

NCT ID NCT07179003

Disease control Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This phase 2 study tests whether adding methylene blue photodynamic therapy (MB-PDT) to standard drainage helps breast abscesses heal faster. Fifty adults with breast abscesses will either receive standard drainage alone or drainage plus MB-PDT. The main goal is to see how quickly symptoms like pain and fever go away.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
methylene blue photodynamic therapy (MB-PDT)
What this could lead to
If it works, this could offer a faster, more effective way to clear breast abscesses and reduce the need for repeat procedures.
What could go wrong
This is a small, early-phase trial with only 50 participants. The added light therapy may not improve outcomes over standard drainage alone and could cause discomfort or skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2027

An estimate. Start dates often move.

Expected to finish

Jun 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults 18 years or older * Clinical signs of breast abscess, including pain, redness, and/or heat of the breast * Approval by the primary care team to pursue PDT and discuss enrollment with the patient Exclusion Criteria: * Pregnancy * Lactation * Allergy to contrast media, narcotics, sedatives, atropine or eggs * Necrotic tissue that requires surgical debridement * Severely compromised cardiopulmonary function or hemodynamic instability * Thrombocytopenia (\<50,000/mm3) * Uncorrectable coagulopathy * Poor kidney function (serum creatinine \>3mg/dl) * Glucose-6-phosphate dehydrogenase (G6PD) deficiency * Patients with hidradenitis suppurativa * Patients with granulomatous mastitis * Unable or unwilling to understand or to provide informed consent * Unable or unwilling to undergo study procedures * Patient unable to cooperate with, or to be positioned for the procedure * Unable to comply with necessary follow up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast abscess are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast abscess

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast abscess

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.